Therapy of human hydatid disease with mebendazole and albendazole (1993)

Peer-Reviewed Study · Teggi A; Lastilla MG; De Rosa F · August 1993

Teggi A et al., 1993-08: Italian multicentre experience of benzimidazole chemotherapy in 337 patients with hydatid cysts (121 on mebendazole, 216 on albendazole), reporting degenerative cyst changes in 50.6% on mebendazole, relapse in about 30%, and side effects that were not severe and always reversible.

Side effects observed with either drug were not severe and always reversible, consisting mainly of abdominal pains and increased levels of transaminases in serum.

1679 (PDF page 1)

Teggi A et al., 1993-08: Italian multicentre experience of benzimidazole chemotherapy in 337 patients with hydatid cysts (121 on mebendazole, 216 on albendazole), reporting degenerative cyst changes in 50.6% on mebendazole, relapse in about 30%, and side effects that were not severe and always reversible. Study type: multicentre clinical study with randomised comparison of mebendazole vs albendazole; N=337 patients total, 216 treated with mebendazole (121 albendazole). Country: Italy (Rome, Policlinico Umberto I / Universita La Sapienza). Mebendazole dose: 50 mg/kg/day in the high-dose group; the paper reports patients on 20-30 mg/kg/day and one on 100 mg/kg/day; treatment 3-12 months. Comparator: albendazole. Funder: not stated in the article. Conflicts: none declared (no disclosure section in the 1993 paper). Product: mebendazole (Vermox, Janssen) named in the paper's methods. Table 8 (p.1682) lists, for mebendazole n=216: elevated SGOT/SGPT, abdominal pain, headache, distension, vertigo, urticaria, jaundice, alopecia, thrombocytopenia, tachycardia, dyspepsia, fever, with the footnote 'Eight patients treated with mebendazole and six treated with albenzadole stopped treatment because of side effects.' Per-reaction counts are printed in a two-column table and were not transcribed into this record to avoid mis-assigning a number to the wrong row.